Can-Fite Biopharma Ltd ADR (CANF) Stock Price, Quote & News

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 924 1114

Fax: 972 3 924 9378

Website: www.canfite.com

Address:

26 Ben Gurion Street, Ramat Gan, Israel

TraTDraHuKa Dec. 7 at 7:28 AM

$CANF

0 · Reply

1AMBITIOUSSAVAGE Dec. 6 at 6:25 PM

$CANF

0 · Reply

ReedThene Dec. 4 at 7:44 PM

$CANF Did this age well?

0 · Reply

Peaceouty Dec. 4 at 6:38 PM

$CANF https://www.channelchek.com/videos/can-fite-biopharma-noblecon21-presentation-replay

1 · Reply

Peaceouty Dec. 4 at 5:08 PM

$CANF Presentations are being uploaded one by one.

1 · Reply

Good_Trade_ Dec. 4 at 11:55 AM

$TNXP $VIVK, $CANF, $CHR.X all cheap, be careful with CHR.

0 · Reply

Majid74 Dec. 4 at 9:39 AM

$CANF 2025-11-25 Can Fite Presentation.pdf https://share.google/zBnmiLoKLoVHO25Lc

0 · Reply

Majid74 Dec. 4 at 9:32 AM

$CANF PT?

1 · Reply

Peaceouty Dec. 4 at 5:35 AM

$CANF They have enough cash to continue operations until 2027 while running 5 trials. There’s like a million catalysts on the way.

0 · Reply

Peaceouty Dec. 3 at 8:55 PM

$CANF Super excited to hear the new presentation tomorrow. I’ll share it once available. Have a good evening!

0 · Reply

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Aug 28, 2025, 8:47 AM EDT - 3 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Jul 30, 2025, 7:04 AM EDT - 4 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Jul 28, 2025, 12:24 PM EDT - 4 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Jul 28, 2025, 7:00 AM EDT - 4 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Apr 17, 2025, 8:55 AM EDT - 8 months ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 14, 2025, 2:28 PM EDT - 8 months ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Mar 20, 2025, 9:45 AM EDT - 9 months ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 19, 2025, 9:00 AM EDT - 9 months ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 3, 2025, 6:00 AM EST - 9 months ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Feb 10, 2025, 7:10 AM EST - 10 months ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 5, 2025, 7:00 AM EST - 10 months ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Dec 30, 2024, 7:00 AM EST - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Nov 11, 2024, 7:00 AM EST - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 4, 2024, 7:08 AM EST - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Oct 18, 2024, 9:06 AM EDT - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 9, 2024, 7:00 AM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Aug 29, 2024, 8:15 AM EDT - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

May 29, 2024, 7:00 AM EDT - 1 year ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 27, 2024, 7:00 AM EDT - 1 year ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 23, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 13, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 10, 2024, 9:00 AM EDT - 1 year ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

May 9, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 6, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Feb 28, 2024, 7:00 AM EST - 1 year ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Jan 30, 2024, 7:00 AM EST - 2 years ago

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Jan 29, 2024, 7:00 AM EST - 2 years ago

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Dec 20, 2023, 7:00 AM EST - 2 years ago

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Dec 4, 2023, 7:00 AM EST - 2 years ago

Can-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Nov 30, 2023, 7:00 AM EST - 2 years ago

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Nov 21, 2023, 1:53 PM EST - 2 years ago

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Nov 21, 2023, 7:00 AM EST - 2 years ago

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

TraTDraHuKa Dec. 7 at 7:28 AM

$CANF

0 · Reply

1AMBITIOUSSAVAGE Dec. 6 at 6:25 PM

$CANF

0 · Reply

ReedThene Dec. 4 at 7:44 PM

$CANF Did this age well?

0 · Reply

Peaceouty Dec. 4 at 6:38 PM

$CANF https://www.channelchek.com/videos/can-fite-biopharma-noblecon21-presentation-replay

1 · Reply

Peaceouty Dec. 4 at 5:08 PM

$CANF Presentations are being uploaded one by one.

1 · Reply

Good_Trade_ Dec. 4 at 11:55 AM

$TNXP $VIVK, $CANF, $CHR.X all cheap, be careful with CHR.

0 · Reply

Majid74 Dec. 4 at 9:39 AM

$CANF 2025-11-25 Can Fite Presentation.pdf https://share.google/zBnmiLoKLoVHO25Lc

0 · Reply

Majid74 Dec. 4 at 9:32 AM

$CANF PT?

1 · Reply

Peaceouty Dec. 4 at 5:35 AM

$CANF They have enough cash to continue operations until 2027 while running 5 trials. There’s like a million catalysts on the way.

0 · Reply

Peaceouty Dec. 3 at 8:55 PM

$CANF Super excited to hear the new presentation tomorrow. I’ll share it once available. Have a good evening!

0 · Reply

Peaceouty Dec. 3 at 8:02 PM

$CANF Plural..

0 · Reply

Peaceouty Dec. 3 at 8:01 PM

$CANF Because everything out there is complete shit! This’s the ONLY drug that has Complete Remissions.

0 · Reply

Peaceouty Dec. 3 at 7:58 PM

$CANF I find it highly interesting on how they are incapable of finding traction with major investors. The drug is even being discussed on Reddit for compassionate use.

0 · Reply

1AMBITIOUSSAVAGE Dec. 3 at 6:38 PM

$ZYXI $CANF RPGL all have 0 Shorts available! 🚀

0 · Reply

Peaceouty Dec. 3 at 5:50 PM

$CANF website is in wheelchair mode.

2 · Reply

Peaceouty Dec. 3 at 12:02 PM

$CANF Can-Fite’s CEO will present on Wednesday, December 3, 2025 at 12:30 PM ET. The presentation will cover the company’s “advanced stage drug development pipeline,” including updates on: Phase III liver cancer, Phase IIa pancreatic cancer, Phase III psoriasis, Phase IIb MASH, and an upcoming Phase II for Lowe Syndrome. 👀👀

0 · Reply

Peaceouty Dec. 2 at 4:15 PM

$CANF “Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson” This’s from their compassionate use program. PR from September. The odds of this happening with current drugs is basically 0. https://finance.yahoo.com/news/fite-reports-complete-resolution-esophageal-110000820.html

0 · Reply

Peaceouty Dec. 2 at 3:58 PM

$CANF Sabby at it’s best. The HF is like a plague for micro caps. Thank god the company has low cash burn and is actively seeking non-dilutive partnerships.

0 · Reply

FeliciaMath Dec. 2 at 3:55 PM

sold $CANF at .36 for 16% gain/$323

0 · Reply

1AMBITIOUSSAVAGE Dec. 2 at 3:55 PM

$CANF

0 · Reply

ALV_pinchytrader Dec. 2 at 2:00 PM

$CANF price target 2$-11$ ???!!!!! Ask google Life changing ….!!!!

0 · Reply

Mr_Squatch Dec. 2 at 1:09 PM

$CANF 200 MA cross coming and then a nice pop, imo! $NDAQ @Stocktwits

0 · Reply

Market Cap	8.20M
Revenue (ttm)	670,000.00
Net Income (ttm)	-7.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,176.12%
Debt to Equity Ratio	0.00

Volume	900,400
Avg Vol	7,957,638
Day's Range	N/A - N/A
Shares Out	26.18M
Stochastic %K	22%
Beta	0.98
Analysts	Strong Sell
Price Target	$6.00